Curtiswyss logo

ANTIBODY DRUG CONJUGATE SUMMIT

May 22 - 23, 2017

The Curtis & Wyss Group is pleased to invite you to the, "Antibody Drug Conjugate summit" scheduled on May 22 - 23, 2017 in Lisbon, Portugal. This innovative B2B event will enable the participants to learn about protein modeling development and engineering advances, preclinical and clinical improvements, current ADC linker chemistry- better linker design for future generations, improving preclinical and clinical translation and creating strong and scalable processes.

It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Lisbon!

Key Practical Learning Points of the Summit:

  • Increase benefits of ADC- dial in potency, target stratified patient populations and optimize dosing regimens
  • Ensure product and process robustness Make more evidence-based decisions
  • Explore alternative opportunities for ADCs by reviewing the potential of using ADCs outside oncology Learn about advances in Protein Modeling and Engineering Breakthroughs
  • How to screen for optimal site of conjugation, select better quality targets and explore new payload mechanisms of action
  • Linker Design Decisions, Novel Payloads and Linker Technology, Next-Generation Chemistry for Improved Conjugation and Linker Stability
  • Characterization of ADCs, Preclinical and Clinical Advances, Translational Considerations
  • Engineering ADCs for Developability, Enhanced Specificity and Binding, and Reduced Toxicity
    

Key Speakers

Dr. Magdalena Dorywalska
Principal Scientist
Pfizer Inc Rinat Laboratories

 

Image result for Pfizer Inc Rinat Laboratories

 

 

Dr. Patrick Robertson
Director, Program Design
FUJIFILM Diosynth Biotechnologies

 

Related image

 

Dr. John Lin, PhD
VP, Bioanalytical and Biologics Services
Frontage Laboratories, Inc

 

Image result for Frontage Laboratories, Inc

 

 

Dr. Roger R. Beerli
Chief Scientific Officer
NBE-Therapeutics AGz

 

Image result for NBE-Therapeutics AG

  

Dr. Chetana Rao, Ph.D
Director,Protein Engineering,
Bristol Myers Squibb

Image result for NBE-Therapeutics AG

Who should attend?

CEOs, Directors, Heads & Managers Of
Leading Application Creators & Suppliers Including:

  • Discovery Chemistry
  • Research & Development
  • Antibody Discovery
  • Toxicology
  • Biologics
  • Protein Engineering
  • Molecular Biology
  • Chief Technology Officer
  • Chief Development Officer
  • Chief Scientific Officer
  • Senior Research Officer
  • Biotherapeutics
  • Oncology Molecules
  • Process Sciences
  • Biopharmaceutical Development
  • Development Analytics and New Technologies
  • Clinical Assay
  • Biologics Discovery and Design

 

 

From Industries Including:

  • Pharmaceuticals
  • Biologics
  • Medicine 
  • Clinical Research Organizations

 

Media Partner


    Allied Market Research

Details

Start:
May 22
End:
May 23

Location

Lisbon, Portugal
Event Programme Request